Samsung Biologics tender offer secures 97.66% of PolyPeptide shares

Bitget2026/11/05 06:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Samsung Biologics’ definitive offer results put Samsung Peptide and parties acting in concert at 32,458,892 PolyPeptide shares, representing 97.99% of capital and voting rights.
By October 30, 2026, tenders totaled 32,350,302 shares: 97.66% of issued capital and voting rights, or 97.98% of shares covered.
Settlement was postponed on November 2; completion is expected toward the end of 2026 or in the first quarter of 2027.
The offer remains subject to outstanding conditions, including regulatory approvals in certain jurisdictions.
Samsung Peptide plans to squeeze out remaining public shareholders and seek delisting following settlement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PolyPeptide Group AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2428776_en) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Samsung Biologics tender offer secures 97.66% of PolyPeptide shares

You may also like

Crypto prices